SCHEMBL22387

SCHEMBL22387

COc1cc(C=O)ccc1F

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.68
TSHR P16473 1/20 0.68
HPGD P15428 2/20 0.61
TRIM24 O15164 1/20 0.61
ALDH5A1 P51649 1/20 0.61
ABAT P80404 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
TRIM33 Q9UPN9 1/20 0.61
FDPS P14324 1/20 0.58
AOX1 Q06278 1/20 0.56
TTR P02766 1/20 0.53
ALDH1A3 P47895 1/20 0.51
AMY1A P0DUB6 1/20 0.51
BACE1 P56817 2/20 0.51
MEN1 O00255 1/20 0.51
POLB P06746 1/20 0.51
KMT2A Q03164 1/20 0.51
GAA P10253 1/20 0.51
CYP2A6 P11509 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435689 0.84 ALDH1A1 (0.68) ALDH1A1TSHRHPGDTRIM24ALDH5A1
SCHEMBL29400600 0.84 ALDH1A1 (0.68) ALDH1A1TSHRHPGDTRIM24ALDH5A1
SCHEMBL7531959 0.84 ALDH1A1 (0.68) ALDH1A1TSHRHPGDTRIM24ALDH5A1
SCHEMBL9995594 0.82 XDH (0.66) ALDH1A1TSHRAMY1ABACE1MAPT
SCHEMBL9995756 0.82 XDH (0.66) ALDH1A1TSHRAMY1ABACE1MAPT
SCHEMBL12495481 0.82 AMY1A (0.53) ALDH1A1TSHRAMY1ABACE1MAPT
3,4-Dimethoxybenzaldehyde SCHEMBL25202 0.81 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL5308959 0.81 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL1330962 0.81 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL29364994 0.81 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1029 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116120182-A Curcumin derivative, synthesis method thereof and application thereof in antiandrogen receptor 常州大学 2023-05-16 CN claimed
CN-112299967-B Preparation method of 3-methoxy-4-fluorobenzaldehyde 无锡双启科技有限公司 2022-04-08 CN claimed
CN-112299967-A Preparation method of 3-methoxy-4-fluorobenzaldehyde 无锡双启科技有限公司 2021-02-02 CN claimed
CN-121990985-A Double-response small molecule fluorescent probe for synchronously detecting NTR and nucleic acid and preparation and application thereof 安徽医科大学 2026-05-08 CN disclosed
EP-4735425-A1 COMPOUNDS Psylo Pty Ltd (AU) 2026-05-06 EP disclosed
US-20260092059-A1 Broad Spectrum Antiviral Compositions and Methods EVRYS BIO, LLC (US) 2026-04-02 US disclosed
EP-4359402-B1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2026-03-11 EP disclosed
EP-4704846-A2 NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2026-03-11 EP disclosed
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
EP-4667471-A2 BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS Evrys Bio, LLC (US) 2025-12-24 EP disclosed
US-20250353818-A1 Compounds Psylo Pty Ltd (AU) 2025-11-20 US disclosed
CN-1321153-A telomerase inhibitors and methods of use thereof GERON CORP (US) 2001-11-07 CN disclosed
WO-2001002377-A9 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORP (US) 2001-10-11 WO disclosed
EP-1140924-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
EP-1109796-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE Geron Corporation (US) 2001-06-27 EP disclosed
WO-2001002377-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2001-01-11 WO disclosed
WO-2000035915-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-06-22 WO disclosed
US-5843983-A Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use SANKYO COMPANY, LIMITED (JP) 1998-12-01 US disclosed
CN-1174190-A Diaryl alkane derivatives containing alicyclic group, their preparation and their therapeutic and prophylactic uses SANKYO CO (JP) 1998-02-25 CN disclosed
EP-0790235-A1 Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses SANKYO COMPANY LIMITED (JP) 1997-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092059-A1 Broad Spectrum Antiviral Compositions and Methods IRF3, ZC3HAV1, ZC3HAV1L ALDH1A1 3002/4885TSHR 682/4885HPGD 4778/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS ALDH1A1 1854/4885TSHR 263/4885HPGD 2903/4885
US-20250353818-A1 Compounds NLN, SLC18A2, PYGB ALDH1A1 981/4885TSHR 1561/4885HPGD 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.